Human mesenchymal stem cells as delivery ofosteoprotegerin gene: homing and therapeutic effect for osteosarcoma

Bo Qiao, Wei Shui, Li Cai, Shuquan Guo, Dianming Jiang Department of Orthopaedics, TheFirst Affiliated Hospital of Chongqing Medical University, Chongqing, People's Republic of China Abstract: Biological treatments have been studied extensively and previous studies have proved that osteoprotege...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Drug design, development and therapy development and therapy, 2015-02, Vol.2015 (default), p.969-976
Hauptverfasser: Qiao B, Shui W, Cai L, Guo SQ, Jiang DM
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Bo Qiao, Wei Shui, Li Cai, Shuquan Guo, Dianming Jiang Department of Orthopaedics, TheFirst Affiliated Hospital of Chongqing Medical University, Chongqing, People's Republic of China Abstract: Biological treatments have been studied extensively and previous studies have proved that osteoprotegerin (OPG) can inhibit the development and progress of human osteosarcoma. However, the utility of biologic agents for cancer therapy has a short half-life, which can hardly deliver to and function in tumor sites efficiently. Mesenchymal stem cells (MSCs) have the potential to migrate to tumor sites. In this study, MSCs transfected with adenoviruses carrying the OPG gene (MSCs-OPG) were used via the tail vein to treat athymic nude mice (nu/nu) bearing osteosarcoma. In vivo and ex vivo images were used to validate the MSCs homing to tumors. The therapeutic effect for osteosarcoma was evaluated by observations on growth of tumors and bone destruction. The results showed that infected MSCs-OPG labeled with red fluorescent protein (RFP) can migrate to tumor sites and express OPG protein. The treatment by MSCs-OPG reduced the tumor growth and inhibited bone destruction in vivo. All these indicated that MSCs can deliver OPG to tumor sites, which could be a new direction of biological treatment for human osteosarcoma. Keywords: therapy, MSC, OPG, bone tumor
ISSN:1177-8881
1177-8881